# US 7,611,910 B2 · Method for diagnosis of alzheimer's disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,611,910 B2
- Document ID: US7611910B2
- Status: Granted
- Kind: B2
- Application number: 11/622,641
- Filed: 2007-01-12
- Published: 2007-06-14
- Granted: 2009-11-03
- Earliest claimed: 1998-01-09
- Assignees: Intracell, LLC
- Inventors: Brian J. Balin; J. Todd Abrams; Alan P. Hudson; Judith A. Whittum-Hudson
- Web page: https://patentgrep.com/patent/US7611910B2

## CPC

- A61K 31/7052: having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/42: Oxazoles
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K 31/5383: ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/65: Tetracyclines
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 31/706: containing six-membered rings with nitrogen as a ring hetero atom
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07K 16/125: {from Chlamydiales (O)}
- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- C07K 2317/77: Internalization into the cell
- G01N 2333/295: from Chlamydiales (o)
- G01N 2800/2821: Alzheimer
- Y10S 436/811: Test for named disease, body condition or organ function
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

The invention relates to a method of treating Alzheimer's disease in a mammal comprising administering to the mammal an anti-microbial agent having anti-Chlamydia pneumoniae activity. The invention also relates to a method of diagnosing Alzheimer's disease in a mammal comprising measuring the serum anti-Chlamydia pneumoniae antibody titer in a patient suspected of having Alzheimer's disease.

## Claims

### Claim 1

A method of diagnosing Alzheimer's disease in a human patient suspected of having Alzheimer's disease, wherein said human does not exhibit symptoms of multiple sclerosis or menginoencephalitis, said method comprising obtaining a cerebrospinal fluid sample from said patient, determining whether said cerebral spinal fluid sample contains Chlamydia pneumoniae, wherein the presence of Chlamydia pneumoniae in said sample is an indication that said patient has Alzheimer's disease.

### Claim 2 (depends on 1)

The method of claim 1, wherein the presence of C. pneumoniae in CSF obtained from the mammal is assessed by a procedure selected from the group consisting of electron microscopy, immunoelectron microscopy, immunohistochemistry, detection of C. pneumoniae DNA or RNA by hybridization, detection of C. pneumoniae DNA or RNA by PCR amplification, RT-PCR amplification, detection of C. pneumoniae nucleic acids using the technique of in situ hybridization, and combinations thereof.